Summary
Unable to evaluate alignment of the AI-generated claims to the FDA label because no AI response text (the exact statements to audit) and no complete TRIJARDY XR label excerpts covering weight change/urination/dehydration/diet/GI effects/weight-loss counseling were provided. The only label content supplied concerns metformin-associated lactic acidosis, which is not the same as the majority of the user claims.
Category Scores
Accurate Statements
Unsupported Statements
SGLT2 inhibitors generally report weight loss as a possible effect.
Not supported by any provided TRIJARDY XR label excerpt in the prompt (only metformin-associated lactic acidosis sections were provided).
SGLT2 inhibitors can lead to modest weight loss in some people.
Not supported by provided label excerpts.
In type 2 diabetes studies of SGLT2-based therapy, weight reduction is commonly seen.
Not supported by provided label excerpts.
The size of weight reduction with SGLT2-based therapy varies by dose.
Not supported by provided label excerpts.
The size of weight reduction with SGLT2-based therapy varies by individual factors such as baseline weight and how well blood sugar is controlled.
Not supported by provided label excerpts.
Most patients who lose weight on SGLT2 inhibitor–containing regimens tend to see small-to-moderate reductions rather than dramatic loss.
Not supported by provided label excerpts.
Weight-change results in the Trijardy XR prescribing information provide an estimate for the exact dose being used.
No weight-change results excerpt for Trijardy XR was provided.
Extra urination from the SGLT2 component can cause dehydration-related changes in scale weight.
No label excerpt addressing urination-related weight/scale changes or dehydration-related scale weight is provided.
Dehydration-related scale changes are not true fat loss.
Not supported by provided label excerpts.
Less calorie intake can occur if blood sugars improve.
Not supported by provided label excerpts.
GI side effects can reduce appetite in some patients.
No GI/appetite counseling excerpt was provided.
Unintentional rapid weight loss warrants contacting a clinician.
No label excerpt providing this specific counseling threshold is provided.
Signs of dehydration (dizziness, fainting, very dry mouth) warrant contacting a clinician.
No dehydration counseling excerpt listing these specific signs is provided.
Persistent nausea/vomiting, abdominal pain, or trouble breathing can be warning signs for serious complications, including rare diabetic ketoacidosis even when glucose is not extremely high.
The provided label excerpts focus on metformin-associated lactic acidosis and do not provide TRIJARDY XR ketoacidosis counseling details. This claim is therefore not supported by the supplied text.
Weight loss is often a benefit in type 2 diabetes.
No such benefit statement is supported by the provided label excerpts.
Some people may not lose weight on Trijardy.
No weight-change variability excerpt was provided.
A minority of people may gain weight depending on factors like diet, other medications, and how their diabetes responds.
No label excerpt supporting weight gain incidence or its drivers was provided.
Contradictions
Low
AI Statement
Persistent nausea/vomiting, abdominal pain, or trouble breathing can be warning signs for serious complications, including rare diabetic ketoacidosis even when glucose is not extremely high.
Label Reference
TRIJARDY XR supplied excerpts include only metformin-associated lactic acidosis warning details; no ketoacidosis “even when glucose is not extremely high” counseling text was provided.
Important Omissions
Metformin-associated lactic acidosis boxed-warning content needed to safely evaluate related safety claims (e.g., symptoms such as malaise/myalgias/abdominal pain/respiratory distress; risk factors; discontinue immediately and supportive measures; prompt hemodialysis).
Importance:
Moderate
TRIJARDY XR-specific weight-change results, dehydration/urination counseling, and any listed patient counseling thresholds for contacting a clinician were not provided in the prompt excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Unknown
Most evaluated claims concern weight change, dehydration/urination, and ketoacidosis counseling, but none of the relevant TRIJARDY XR label sections for these topics were provided. Only metformin-associated lactic acidosis warning content is included in the prompt, so the overall risk of mislabel-adherence cannot be determined from the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable
Primary Issue
Insufficient label evidence provided for the majority of claims (weight change, urination/dehydration effects, appetite/GI effects, and ketoacidosis counseling). Only metformin-associated lactic acidosis excerpts were supplied.
Suggested Improvement
Provide the AI-generated response text to audit and include TRIJARDY XR label excerpts covering weight change outcomes and patient counseling for dehydration/serious complications (e.g., SGLT2-related adverse reactions and ketoacidosis counseling) so each claim can be checked against specific on-label wording.